Bloodstream infections due to vancomycinresistant enterococcal species (VRE-BSI) can be a lethal complication for hospitalized patients.VRE-BSI principally affects vulnerable patient populations, including complex postsurgical and internal medicine patients with multiple comorbid conditions [1][2][3][4][5][6].VRE-BSI has particularly high attributable mortality in hematopoietic stem cell transplant recipients, liver transplant recipients, oncology patients, and other critically ill hospitalized populations [5][6][7][8][9][10][11][12][13].Despite the high human and economic burden of VRE-BSI, the optimal treatment for these infections has not been established,